 - Concomitant therapy with drugs or other products known to alter the activity of hepatic or intestinal microsomal enzymese.g., inducers or inhibitors of CYPs 1A2, 2D6, andor 3A4, P-glycoprotein or potential competing substrates for the CYPs, under study within 7 days of a scheduled phenotyping evaluation 